The morphology strikes back

“Molecular trumps morphology” was the slogan for the WHO classification of Central Nervous System (CNS) tumors updated in 2016 (CNS4+) and is even more applicable for the current WHO classification (CNS5).1,2 As one of many implications, albeit certainly not the clinically most far-reaching, neuropa...

Full description

Saved in:
Bibliographic Details
Main Author: Sahm, Felix (Author)
Format: Article (Journal) Editorial
Language:English
Published: September 2024
In: Neuro-Oncology
Year: 2024, Volume: 26, Issue: 9, Pages: 1543-1544
ISSN:1523-5866
DOI:10.1093/neuonc/noae124
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/neuonc/noae124
Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/neuro-oncology/article/26/9/1543/7713108
Get full text
Author Notes:Felix Sahm
Description
Summary:“Molecular trumps morphology” was the slogan for the WHO classification of Central Nervous System (CNS) tumors updated in 2016 (CNS4+) and is even more applicable for the current WHO classification (CNS5).1,2 As one of many implications, albeit certainly not the clinically most far-reaching, neuropathologists are asked whether they even need H&E sections anymore (which often is only a covert attempt to question the need for the neuropathologists themselves). On the contrary, how all these novel tests underlying the newly introduced biomarkers can be afforded in routine care is a pressing question, given the typically large equipment and reagent cost. In fact, these requirements have even been debated as incompatible with the goals and mandate of a World Health Organization guideline.3,4
Item Description:Online veröffentlicht: 13. Juli 2024
Gesehen am 29.11.2024
Physical Description:Online Resource
ISSN:1523-5866
DOI:10.1093/neuonc/noae124